230 related articles for article (PubMed ID: 17652812)
1. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
2. Novel antioxidants in anthracycline cardiotoxicity.
Hideg K; Kálai T
Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
[TBL] [Abstract][Full Text] [Related]
3. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
[TBL] [Abstract][Full Text] [Related]
4. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
5. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
7. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical aspects.
Formigari A; Irato P; Santon A
Comp Biochem Physiol C Toxicol Pharmacol; 2007 Nov; 146(4):443-59. PubMed ID: 17716951
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein.
Liu Q; Wang G; Zhou G; Tan Y; Wang X; Wei W; Liu L; Xue W; Feng W; Cai L
Toxicol Lett; 2009 Dec; 191(2-3):314-20. PubMed ID: 19808082
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
10. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
[TBL] [Abstract][Full Text] [Related]
11. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
DiSilvestro RA; Liu J; Klaassen CD
Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
[TBL] [Abstract][Full Text] [Related]
13. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
14. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
15. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity.
Wattanapitayakul SK; Chularojmontri L; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Bauer JA
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):80-7. PubMed ID: 15667600
[TBL] [Abstract][Full Text] [Related]
16. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
Li L; Pan Q; Han W; Liu Z; Li L; Hu X
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6753-60. PubMed ID: 18006777
[TBL] [Abstract][Full Text] [Related]
17. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
[TBL] [Abstract][Full Text] [Related]
18. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
Horenstein MS; Vander Heide RS; L'Ecuyer TJ
Mol Genet Metab; 2000; 71(1-2):436-44. PubMed ID: 11001837
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]